End-Stage Kidney Disease Clinical Trial
Official title:
Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis
Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of Endoplasmic reticulum (ER) stress may be responsible for progressive membrane dysfunction. Ursodeoxycholic acid (URSA) is a powerful inhibitor of ER stress to protect peritoneal fibrosis in peritoneal dialysis in the investigators in-vitro study. In this study the researchers investigated the hypothesis that URSA protect peritoneal membrane damage.
Ursodeoxycholic acid (URSA) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 300 mg per day. Patients will be randomly assigned to URSA and placebo group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test (PET) will be performed with blood sampling. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
| Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
| Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
| Completed |
NCT02694068 -
Biological Determinants of Peritoneal Dialysis
|
||
| Not yet recruiting |
NCT02832505 -
Applications of MRI in Kidney Disease
|
||
| Not yet recruiting |
NCT02590081 -
Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT01859884 -
Optimizing Kidney Transplant Informed Consent
|
N/A | |
| Completed |
NCT00509236 -
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
|
Phase 3 | |
| Completed |
NCT02009514 -
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06377293 -
Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients
|
N/A | |
| Completed |
NCT01528800 -
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
|
Phase 2 | |
| Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
| Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
| Completed |
NCT04610593 -
Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis
|
N/A | |
| Recruiting |
NCT05931276 -
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
|
Phase 3 | |
| Completed |
NCT00143741 -
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
|
Phase 1 | |
| Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
| Recruiting |
NCT03142529 -
Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02342119 -
Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation
|
N/A | |
| Recruiting |
NCT05614115 -
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
|
Phase 1 |